Skip to Main Content

Author Details

Anna C Schinzel
2004
34
28
PMIDPaper TitleJournal TitlePublished Year
34810201Plasticity in the Absence of NOTCH Uncovers a RUNX2-Dependent Pathway in Small Cell Lung Cancer.Cancer Res2022
30777879MCL1 and DEDD Promote Urothelial Carcinoma Progression.Mol Cancer Res2019
31727771The KDM5A/RBP2 histone demethylase represses NOTCH signaling to sustain neuroendocrine differentiation and promote small cell lung cancer tumorigenesis.Genes Dev2019
27899381Castration Resistance in Prostate Cancer Is Mediated by the Kinase NEK6.Cancer Res2017
28447610PARP3 is a promoter of chromosomal rearrangements and limits G4 DNA.Nat Commun2017
28607496Corrigendum: PARP3 is a promoter of chromosomal rearrangements and limits G4 DNA.Nat Commun2017
24909179PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling.Oncogene2015
25535366An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma.Proc Natl Acad Sci U S A2015
26499495Functional genomic screening reveals asparagine dependence as a metabolic vulnerability in sarcoma.Elife2015
24747640Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation.Nat Genet2014
24444711Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit.Cancer Discov2014
24954536KRAS and YAP1 converge to regulate EMT and tumor survival.Cell2014
23322301Integrated cistromic and expression analysis of amplified NKX2-1 in lung adenocarcinoma identifies LMO3 as a functional transcriptional target.Genes Dev2013
23764425Systematic interrogation of 3q26 identifies TLOC1 and SKIL as cancer drivers.Cancer Discov2013
23245941β-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis.Cell2012
22730461Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesis.Proc Natl Acad Sci U S A2012
22684105Tyrosine kinase pathways modulate tumor susceptibility to natural killer cells.J Clin Invest2012
22326953The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemia.J Clin Invest2012
21889194BET bromodomain inhibition as a therapeutic strategy to target c-Myc.Cell2011
21430775Initial genome sequencing and analysis of multiple myeloma.Nature2011
20126544CK1epsilon is required for breast cancers dependent on beta-catenin activity.PLoS One2010
20227043An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells.Cancer Cell2010
19847166Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1.Nature2009
19364473Integrative genomic approaches to understanding cancer.Biochim Biophys Acta2009
19182807The peptidyl-prolyl isomerase Pin1 facilitates cytokine-induced survival of eosinophils by suppressing Bax activation.Nature Immunology2009
19490892Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells.Cell2009
19573809AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer.Cancer Cell2009
19800574Proteomic and genetic approaches identify Syk as an AML target.Cancer Cell2009
17981529Oncogenic transformation and experimental models of human cancer.Front Biosci2008
16645094RETRACTED: Proapoptotic BAX and BAK modulate the unfolded protein response by a direct interaction with IRE1alpha.Science2006
16103352Cyclophilin D is a component of mitochondrial permeability transition and mediates neuronal cell death after focal cerebral ischemia.Proceedings of the National Academy of Sciences of the United States of America2005
15037603Conformational control of Bax localization and apoptotic activity by Pro168.Journal of Cell Biology2004
14996494Bcl-2 family members: integrators of survival and death signals in physiology and pathology [corrected].2004
14729175Bcl-w(edding) with mitochondria.Trends in Cell Biology2004
  • 1 - 34 of 34

Recommended Authors

Collaborators

Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute
Co-authored papers 26
Broad Institute of Harvard and MIT
Co-authored papers 9
Broad Institute of Harvard and MIT
Co-authored papers 6
Co-authored papers 5
Co-authored papers 5
Co-authored papers 5
University of California San Diego
Co-authored papers 4
Co-authored papers 4
Vanderbilt-Ingram Cancer Center, Vanderbilt University
Co-authored papers 4
University of California San Diego
Co-authored papers 4
Broad Institute
Co-authored papers 4
Broad Institute of Harvard and MIT
Co-authored papers 3
Co-authored papers 3
Merck & Co.
Co-authored papers 3
Janssen Research and Development LLC
Co-authored papers 3
Co-authored papers 3
Dana-Farber Cancer Institute
Co-authored papers 3
Co-authored papers 2
Dana-Farber Cancer Institute
Co-authored papers 2
Memorial Sloan Kettering Cancer Center
Co-authored papers 2
Dana Farber Cancer Institute
Co-authored papers 2
Co-authored papers 2
Broad Institute of MIT and Harvard
Co-authored papers 2
Broad Institute of MIT and Harvard
Co-authored papers 2
Novartis Institutes for BioMedical Research
Co-authored papers 2
Dana-Farber Cancer Institute
Co-authored papers 2
University of Pennsylvania School of Medicine
Co-authored papers 2
Dana-Farber Cancer Institute
Co-authored papers 2
Co-authored papers 2
National Cancer Institute
Co-authored papers 2